Drugs / WSK-IM02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07615894 | Jun 2026 → Jan 2028 expected | peritoneal neoplasm, pleural disorder | WestVac Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07462468 | Mar 2026 → Mar 2027 expected | carcinoma | WestVac Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WSK-IM02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07615894 ↗ |
| Route | Other | “via intraperitoneal injection” NCT07462468 ↗ |